Objectives
Spinal muscular atrophy (SMA) is caused by reduced levels of SMN which results
in motoneuron loss. Therapeutic strategies to increase SMN levels including drug
compounds, antisense oligonucleotides or scAAV9 gene therapy have proved effective in
mice. We wished to determine whether reduction of SMN in postnatal motoneurons resulted
in SMA in a large animal model, whether SMA could be corrected after development of
muscle weakness and the response of clinically relevant biomarkers.
Methods
Using intrathecal delivery of scAAV9 expressing a shRNA targeting pig
SMN1, SMN was knocked down in motoneurons postnatally to SMA levels.
This resulted in an SMA phenotype representing the first large animal model of SMA.
Restoration of SMN was performed at different time points with scAAV9 expressing human
SMN (scAAV9-SMN) and electrophysiology measures and pathology were performed.
Results
Knockdown of SMN in postnatal motoneurons results in overt proximal weakness,
fibrillations on electromyography (EMG) indicating active denervation, and reduced
compound muscle action potential (CMAP) and motor unit number estimates (MUNE), like
human SMA. Neuropathology showed loss of motoneurons and motor axons. Pre-symptomatic
delivery of scAAV9-SMN prevented SMA symptoms indicating all changes are SMN dependent.
Delivery of scAAV9-SMN after symptom onset had a marked impact on phenotype,
electrophysiological measures and pathology.
Interpretation
High SMN levels are critical in postnatal motoneurons and reduction of SMN
results in a SMA phenotype which is SMN dependent. Importantly, clinically relevant
biomarkers including CMAP and MUNE are responsive to SMN restoration and abrogation of
phenotype can be achieved even after symptom onset.